Journal of Microbial & Biochemical Technology

Prophylactic effects of Bifidobacterium bifidum (strains of human origin), probiotic feeding on Escherichia coli O157:H7 infection, in rats (in vivo antagonism)

International Conference and Summit on Industrial & Pharmaceutical Microbiology

October 17-18, 2016 Kuala Lumpur, Malaysia

Mahmoudi F and Hedadji M

University of Mostaganem, Algeria

Posters & Accepted Abstracts: J Microb Biochem Technol

Abstract:

The B. bifidum strain (Bf1) was isolated on MRS medium contained 0.5 g/L of cysteine hydrochloride, 2 mg/L of nalidixic acid and 0.1 mg of mupirocin. This strain was isolated from (breastfed infant feces). The effectiveness of Bifidobacterium bifidum Bf1 as a probiotic against enterohemorrhagic Escherichia coli O157:H7 infection was studied using the rats model, were fed the probiotic for 7 days before or after single challenge with E. coli O157:H7. Fecal B. bifidum Bf1 and E. coli O157:H7 counts obtained by selective culturing methods were assessed for 1 week before and after infection while feed intake, body weight and composition were monitored during 1 week after infection. Histology of gut tissue (intestine) was analyzed until 1 and 2 weeks post infection, respectively. The pathogenicity of E. coli O157:H7, marked by body weight loss and intestinal histopathological changes in the infected group was significantly reduced in the B. bifidum treated group. Feeding B. bifidum Bf1 for 7 days before infection resulted in greater post challenge feed intake and weight gain and lower fecal levels of E. coli O157:H7. A lesser degree of protection against E. coli O157:H7 infection was observed when bifidobacteria were given during the 7 days after E. coli O157:H7 infection. These results demonstrate that feeding the probiotic B. bifidum Bf1 to rat can reduce the severity of E. coli O157:H7 infection and suggest that this strain represents a good candidate for the prevention of enteric infections in human.

Biography :

Email: mahmoudifatima70@yahoo.fr